GlassScriptPhysician profile
Desiree Moro
NPI 1023656956
$4,821.92
in general payments reported to CMS, 2019-2025
41 companies · $164 in 2025
The $164 reported for 2025 was more than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $116 · 2022: $1,117 · 2023: $3,357 · 2024: $67.10 · 2025: $164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,588.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,588.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $858.85 | 2021-2023 | |
| Lilly USA, LLC | $405.43 | 2022-2023 | Emgality, Reyvow, Amyvid |
| Emd Serono, INC. | $400.54 | 2022-2023 | Mavenclad |
| Biogen, INC. | $386.16 | 2022-2023 | Vumerity, Tysabri, Tecfidera |
| Lundbeck LLC | $322.66 | 2022-2023 | Vyepti |
| Argenx US, INC. | $301.09 | 2022-2023 | Vyvgart, Vyvgart Hytrulo |
| Harmony Biosciences LLC | $251.92 | 2022-2023 | Wakix |
| Neurocrine Biosciences, INC. | $243.14 | 2022-2023 | Ongentys, Ingrezza |
| Teva Pharmaceuticals USA, INC. | $178.78 | 2022-2023 | Austedo Xr, Austedo |
| Medtronic, INC. | $164.29 | 2025 | Linq II |
| Novartis Pharmaceuticals Corporation | $101.45 | 2023 | |
| Tg Therapeutics, INC. | $100.00 | 2023 | |
| Ge Healthcare | $87.92 | 2023-2024 | |
| Neurelis, INC. | $85.29 | 2023 | Valtoco |
| Averitas Pharma INC. | $68.01 | 2023 | Qutenza |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Desiree Moro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.